- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03338114
Study to Evaluate the Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Upper or Lower Extremity Muscles Most Affected in Subjects With ALS
January 18, 2018 updated by: Flex Pharma, Inc.
An Open Label Study to Evaluate the Safety and Efficacy of FLX-787-ODT for Treatment of Fasciculations in the Tongue and Upper or Lower Extremity Muscles Most Affected in Subjects With Amyotrophic Lateral Sclerosis (ALS)
The FLX-787-106 study will determine how well FLX-787-ODT works to reduce fasciculations in patients with Amyotrophic Lateral Sclerosis (ALS).
The study will measure how often fasciculations occur, and monitor any side effects that might develop while taking the investigational product.
Participants will be assessed before and after taking a single dose of FLX-787-ODT.
Approximately 15 people will take part in this study at one center in the United States.
Participants will be in the study for a single clinic visit and receive a telephone call 7 days later to monitor for side effects.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Wake Forest University Health Sciences
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Documented diagnosis of ALS diagnosis of less than 3 years.
- Expected survival > 6 months
- Frequent fasciculations noted during clinical examination of any single muscle (>6 visible fasciculations per minute) observed in Part I
- Normal oral cavity exam at screening
- Proficient in English
- Male subjects will either be surgically sterile or agree to use a medically acceptable method of contraception during sexual contact with females of childbearing potential, and will refrain from sperm donation for 45 days following the study
- Male subjects will either be surgically sterile or agree to use a medically acceptable method of contraception during sexual contact with females of childbearing potential, and will refrain from sperm donation for 45 days following the study
Exclusion Criteria:
- Presence of clinically significant or unstable condition that would result in an increased risk of study participation or difficulty in interpretation of the study results
- Tremor or other movement disorder that would interfere with recording
- Inability to lie flat
- Presence of major gastrointestinal disorders, such as inflammatory bowel disease, diverticulitis, active peptic ulcer disease, or significant gastroesophageal reflux disease (i.e., not well-controlled on antacids or proton pump inhibitors), or oral or esophageal lesions/ulcers
- Presence of laryngospasm or significant swallowing problems
- Presence of percutaneous endoscopic gastrostomy, esophagogastroduodenoscopy, or G-tube
- Inability to tolerate a spicy sensation in the mouth or stomach
- Actively using illicit drugs or history of chronic substance abuse within the past year prior to screening, including abuse of alcohol
- Participated in a clinical study (except natural history studies without administration of an investigational product) within 30 days prior to screening
- Pregnant, breastfeeding, or planning to become pregnant
- Blood pressure of ≥160 mmHg systolic and/or ≥100 mmHg diastolic
- Clinically significant abnormalities in laboratory findings (including screening complete electrolyte panel, complete blood count, liver function tests).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: FLX-787-ODT (orally disintigrating tablet)
|
Oral Disintegrating Tablet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline of Diastolic Blood Pressure in mmHg
Time Frame: Prior to and within 3 hours following administration of investigational product on the single clinic visit
|
Diastolic blood pressure collected before and after treatment
|
Prior to and within 3 hours following administration of investigational product on the single clinic visit
|
Change from Baseline of Systolic Blood Pressure in mmHg
Time Frame: Prior to and within 3 hours following administration of investigational product on the single clinic visit
|
Systolic blood pressure collected before and after treatment
|
Prior to and within 3 hours following administration of investigational product on the single clinic visit
|
Change from Baseline in Heart Rate in beats per minute
Time Frame: Prior to and within 3 hours following administration of investigational product on the single clinic visit
|
Heart rate collected before and after treatment
|
Prior to and within 3 hours following administration of investigational product on the single clinic visit
|
Change from Baseline in Respiration Rate in breaths per minute
Time Frame: Prior to and within 3 hours following administration of investigational product on the single clinic visit
|
Respiration rate collected before and after treatment
|
Prior to and within 3 hours following administration of investigational product on the single clinic visit
|
Change from Baseline in Body Temperature in degrees Celsius or Fahrenheit
Time Frame: Prior to and within 3 hours following administration of investigational product on the single clinic visit
|
Body temperature collected before and after treatment
|
Prior to and within 3 hours following administration of investigational product on the single clinic visit
|
Change from Baseline of Oral Cavity Examination
Time Frame: Prior to and twice within 4 hours following administration of investigational product on the clinic visit
|
Oral Cavity Examination performed before and after treatment
|
Prior to and twice within 4 hours following administration of investigational product on the clinic visit
|
Incidence of Treatment-Emergent Adverse Events
Time Frame: Prior to and following administration of investigational product on the clinic visit with AEs followed for 7 days after by telephone contact
|
Adverse Event Information collected throughout the study
|
Prior to and following administration of investigational product on the clinic visit with AEs followed for 7 days after by telephone contact
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline of Fasciculation Frequency
Time Frame: Prior to and twice within 4 hours following administration of investigational product on the clinic visit
|
Fasciculations over time measured by ultrasound before and after treatment
|
Prior to and twice within 4 hours following administration of investigational product on the clinic visit
|
Change from Baseline of Fasciculation Frequency
Time Frame: Prior to and twice within 4 hours following administration of investigational product on the clinic visit
|
Fasciculations over time measured by EMG before and after treatment
|
Prior to and twice within 4 hours following administration of investigational product on the clinic visit
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
November 1, 2017
Primary Completion (Anticipated)
August 1, 2018
Study Completion (Anticipated)
August 1, 2018
Study Registration Dates
First Submitted
November 6, 2017
First Submitted That Met QC Criteria
November 6, 2017
First Posted (Actual)
November 9, 2017
Study Record Updates
Last Update Posted (Actual)
January 23, 2018
Last Update Submitted That Met QC Criteria
January 18, 2018
Last Verified
November 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Metabolic Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Neuromuscular Diseases
- Neurodegenerative Diseases
- Neuromuscular Manifestations
- Spinal Cord Diseases
- TDP-43 Proteinopathies
- Proteostasis Deficiencies
- Sclerosis
- Motor Neuron Disease
- Amyotrophic Lateral Sclerosis
- Fasciculation
Other Study ID Numbers
- FLX-787-106
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Amyotrophic Lateral Sclerosis
-
Washington University School of MedicineMassachusetts General HospitalSuspendedAmyotrophic Lateral Sclerosis, Familial | Amyotrophic Lateral Sclerosis, SporadicUnited States
-
University of Sao Paulo General HospitalPontifícia Universidade Católica do ParanáUnknownAMYOTROPHIC LATERAL SCLEROSISBrazil
-
Institut de Recherche sur la Moelle épinière et...Groupe Hospitalier Pitie-Salpetriere; Institut de Myologie, France; Association... and other collaboratorsRecruitingALS - Amyotrophic Lateral SclerosisFrance
-
ZIWIGMonitoring Force GroupRecruitingAmyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis, SporadicFrance
-
Charite University, Berlin, GermanyMax Planck Institute for Infection BiologyCompletedAmyotrophic Lateral Sclerosis (ALS)Germany
-
Charite University, Berlin, GermanyCompletedAmyotrophic Lateral Sclerosis (ALS)Germany
-
Mitsubishi Tanabe Pharma America Inc.CompletedAmyotrophic Lateral Sclerosis (ALS)United States, Canada, Japan, France, Germany, Italy
-
AB ScienceCompletedAmyotrophic Lateral Sclerosis (ALS)Spain
-
Eisai Co., Ltd.CompletedAmyotrophic Lateral Sclerosis (ALS)Japan
-
Barrow Neurological InstituteALS Association; Muscular Dystrophy Association; Synapse BiomedicalCompletedAmyotrophic Lateral Sclerosis (ALS)United States
Clinical Trials on FLX-787-ODT (orally disintigrating tablet)
-
Flex Pharma, Inc.TerminatedCharcot-Marie-Tooth DiseaseUnited States
-
Flex Pharma, Inc.TerminatedMotor Neuron DiseaseUnited States
-
Flex Pharma, Inc.TerminatedAmyotrophic Lateral Sclerosis | FasciculationUnited States
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyCompletedSickle Cell DiseaseUnited States
-
Yonsei UniversityRecruitingClinical Trial to Evaluate the Efficacy and Safety of Suvaro®OD Tablet in Patients With DyslipidemiaDyslipidemiaKorea, Republic of
-
MonoSol RxCompletedNausea With Vomiting Chemotherapy-Induced | Nausea and Vomiting, PostoperativeIndia